Compare S&P500 ETF (SPY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs TransMedics Group Inc — how do they compare? S&P500 ETF trades at $778.86 (market cap $821.54B), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: S&P500 ETF is far larger — about 299.8× TransMedics Group Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and TransMedics Group Inc for 24 Days on average.
| SPY | TMDX | |
|---|---|---|
Market Cap | $821.54B | $2.74B |
Volume | 40,070,358 | 949,331 |
52-Week High | $779.14 | $150.42 |
52-Week Low | $631.99 | $61.99 |
Typical Hold Time | 205 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY (SPDR S&P 500 ETF Trust) trades at $778.18, up 0.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.54 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates and profit growth expectations of 35% for 2026. Technical support sits at $771 with resistance at $777.
Outlook remains cautiously optimistic given the ETF's broad market exposure, though risks include potential profit growth deceleration to 15% in 2027 and market-wide valuation concerns. The dividend yield of approximately 0.24% provides modest income, while institutional positioning favors large-cap stability amid economic uncertainty.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
